We currently employ approximately 1,450 full time employees across the country, providing a salary injection of $157 million into the Canadian economy. We have two divisional headquarters in Mississauga, Ontario and Montréal, Quebec, and an administrative office in Quebec City.
The Ste-Foy vaccine manufacturing site currently produces an important share of Canada’s seasonal influenza vaccine and responsible for the domestic supply of the country’s pandemic influenza vaccine requirements.
Research & development
We have invested more than $2 billion since 2001 in Canadian pharmaceutical and vaccines Research & Development (R&D), with over 109 million in 2022 alone. In 2022, we invested over $21 million into 54 active clinical trials across Canada involving 3,700 active subjects.
We are committed to working in partnership with charities and community based organizations who reflect our key values, supporting programs with a local, national or international reach.
In October 2018, we launched a Centralized Waste program involving the removal of individual waste containers from offices to promote environmental consciousness and reduce our contribution to landfills.
In November 2020, as a global biopharmaceutical company we announced ambitious new environmental sustainability goals in both climate and nature, aiming to have a net zero impact on climate and a net positive impact on nature by 2030, across our entire value chain – from lab to patient. We’ve set clear and measurable targets to help achieve these goals.